Evidence map›Paper›PMID 42324256›Full record

ArticleNature communications2026

A unified platform for the rapid assembly of glutarimides for Cereblon E3 ligase modulatory drugs.

David M Whalley, Olivier Lorthioir, Niall A Anderson, Erin Braybrooke, Susannah C Coote, Sylvain Demanze, Holly L Douglas, Okky Dwichandra Putra, Katie Proctor, Yuanyuan Si and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

David M WhalleyOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK. david.whalley2@astrazeneca.com.ORCID http://orcid.org/0000-0002-5988-7457
Olivier LorthioirOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK. olivier.lorthioir@astrazeneca.com.ORCID http://orcid.org/0000-0003-4191-4522
Niall A AndersonOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0001-8403-9698
Erin BraybrookeOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.
Susannah C CooteDepartment of Chemistry, University of Bath, Claverton Down, Bath, UK.ORCID http://orcid.org/0000-0002-3590-9113
Sylvain DemanzeOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0003-4533-6280
Holly L DouglasOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.
Okky Dwichandra PutraEarly Product Development and Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Pepparedsleden 1, Mölndal, Sweden.ORCID http://orcid.org/0000-0002-6968-1858
Katie ProctorOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.
Yuanyuan SiBiopharmaceuticals R&D, AstraZeneca, 35 Gatehouse Dr, Waltham, MA, USA.
Sam StanilandOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.
Stephen StokesOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.
Alfie WoodhouseOncology R&D, The Discovery Centre, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutarimide-containing Cereblon (CRBN) ligands are critical motifs for PROTACs, molecular glue degraders and next-generation Cereblon E3 ligase modulatory drugs (CELMoDs), which represent promising therapeutic modalities in targeted protein degradation. However, the multistep synthetic routes required to access glutarimide scaffolds continue to present formidable challenges for medicinal chemists, limiting rapid structure-activity relationship (SAR) exploration and late-stage diversification. To streamline access to these privileged motifs, modular and efficient methodologies are still highly desirable. Here, we report a unified organocatalytic synthesis platform for the rapid assembly of diverse glutarimide derivatives from readily available nitrogen heterocycles. Employing a sequence of phosphine-catalysed C-N bond formation, metal-free Giese addition and acid-mediated cyclisation, this approach provides high selectivity, broad functional group tolerance and operational simplicity under conditions amenable to both multigram synthesis and high-throughput parallel synthesis. Using this platform, we rapidly prepare CRBN binder libraries, access control analogues (for example, N‑alkylated glutarimides) and perform late‑stage functionalisation of bioactive molecules. This strategy could offer a transformative solution for the efficient and cost-effective synthesis of CRBN-targeted therapeutics and chemical biology probes, overcoming longstanding synthetic bottlenecks in the field.

Indexed as

Adaptor Proteins, Signal TransducingPeptide HydrolasesPiperidonesUbiquitin-Protein LigasesHumansLigandsProteolysis Targeting ChimeraStructure-Activity RelationshipAdaptor Proteins, Signal TransducingCRBN protein, humanglutarimideLigandsPeptide HydrolasesPiperidonesProteolysis Targeting ChimeraUbiquitin-Protein Ligases

Identifiers

PMID42324256
PMCPMC13439528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.